菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Newsletter: June 2021

WuXi Biologics Completed Three Acquisitions to Enhance its Global Network

Facilities and Operations

WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services Read More

WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA) Read More

 

WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA Read More

 

WuXi Biologics Receives GMP Certification from Brazil’s ANVISA Read More

 

The World’s Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics Read More


Resources

The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. View this Podcast

Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions (Webinar)

 

Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines (Webinar)

 

Applications and Impact of CRISPR/Cas9 in Bioprocessing  (Podcast)

 

Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform (White Paper)

 

Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms (Podcast)

 

Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up (White Paper)


Partner News

 

WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates Read More

 

WuXi Biologics Congratulates Emergency Use Authorization of Sotrovimab for the treatment of COVID-19 Read More

 

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Read More

 

WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Read More

 

WuXi Biologics, WuXi STA and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage Read More


Awards

WuXi Biologics Named China’s Most Attractive Employer Read More